NURIX THERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
NURIX THERAPEUTICS, INC. (NRIX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$133.64 million for the 9-month period ending 2022-08-31, per its 10-Q filed 2022-10-06.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2022-10-06
- NURIX THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-08-31 was -$45.71M.
- NURIX THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-05-31 was -$45.40M.
- NURIX THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-02-28 was -$42.53M.
- NURIX THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-11-30 was -$37.70M.
- NURIX THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$117.19M.
- NURIX THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$43.24M.
- NURIX THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2019 was -$21.70M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-08-31 | -$45.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | -$91.11M derived: sum of 2 quarters · filed 2022-10-06 | -$133.64M 10-Q · filed 2022-10-06 | -$171.34M derived: sum of 4 quarters · filed 2022-10-06 |
| 2022-05-31 | -$45.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | -$87.93M 10-Q · filed 2022-07-07 | -$125.64M derived: sum of 3 quarters · filed 2022-07-07 | -$154.47M derived: sum of 4 quarters · filed 2022-10-06 |
| 2022-02-28 | -$42.53M 10-Q · filed 2022-04-08 | -$80.23M derived: sum of 2 quarters · filed 2022-04-08 | -$109.07M derived: sum of 3 quarters · filed 2022-10-06 | -$135.45M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-11-30 | -$37.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$66.54M derived: sum of 2 quarters · filed 2022-10-06 | -$92.92M derived: sum of 3 quarters · filed 2022-10-06 | -$117.19M 10-K · filed 2022-01-28 |
| 2021-08-31 | -$28.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | -$55.22M derived: sum of 2 quarters · filed 2022-10-06 | -$79.49M 10-Q · filed 2022-10-06 | -$99.41M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | -$26.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | -$50.66M 10-Q · filed 2022-07-07 | -$70.57M derived: sum of 3 quarters · filed 2022-07-07 | -$89.09M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | -$24.27M 10-Q · filed 2022-04-08 | -$44.19M derived: sum of 2 quarters · filed 2022-04-08 | -$62.71M derived: sum of 3 quarters · filed 2022-04-08 | -$55.13M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | -$19.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$38.43M derived: sum of 2 quarters · filed 2022-01-28 | -$30.85M derived: sum of 3 quarters · filed 2022-01-28 | -$43.24M 10-K · filed 2022-01-28 |
| 2020-08-31 | -$18.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | -$10.94M derived: sum of 2 quarters · filed 2021-10-14 | -$23.33M 10-Q · filed 2021-10-14 | -$36.85M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $7.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-13 | -$4.81M 10-Q · filed 2021-07-13 | -$18.33M derived: sum of 3 quarters · filed 2022-01-28 | |
| 2020-02-29 | -$12.39M 10-Q · filed 2021-04-13 | -$25.91M derived: sum of 2 quarters · filed 2022-01-28 | ||
| 2019-11-30 | -$13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$21.70M 10-K · filed 2022-01-28 | ||
| 2019-08-31 | -$8.18M 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |